XVIVO Q2: A roaring quarter - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

XVIVO Q2: A roaring quarter - Redeye

{newsItem.title}

XVIVO delivered a positive surprise in Q2 with organic growth of 35% which was well ahead of the already improved earlier quarter, Redeye’s expectations and the market expectations. Possibly also ahead of XVIVO’s expectations. The overall gross margin was a healthy 75% and EBITDA was a substantial positive surprise. This is even more reassuring as XVIVO will improve its structural support gradually after Q3 2024 in our view. We expect a substantial share price reaction and XVIVO is well placed ahead of 2025.

Länk till analysen i sin helhet: https://www.redeye.se/research/1021482/xvivo-q2-a-roaring-quarter?utm_source=finwire&utm_medium=RSS

Nyheter om Xvivo Perfusion

Läses av andra just nu

Om aktien Xvivo Perfusion

Senaste nytt